Shares in Monte Rosa Therapeutics (NASDAQ:GLUE) climbed around 13% after the company released encouraging interim results from a Phase 1 study of its experimental drug MRT-8102, pointing to a marked ...

Clinical-stage biotechnology company Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) on Wednesday revealed interim data from an ...

CRP levels below 2 mg/L, a threshold associated with lower cardiovascular risk. ・Safety data were favorable, with adverse events that were mild to moderate, self-resolving, and not dose-dependent.

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment ...

Taking probiotics and magnesium together is considered safe and may help with mood and the gut microbiome. It's not ...

Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...

Response and remission rates failed to beat placebo in a new Harvard meta-analysis, throwing the inflammation hypothesis into ...

C-reactive protein is created by the liver in response to infections, tissue damage, chronic inflammatory states from ...

Heart disease is the leading cause of death in the United States. Since researchers first established the link between diet, cholesterol and heart disease in the 1950s, risk for heart disease has been ...

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Mary J. Scourboutakos, Macon & Joan Brock Virginia Health Sciences at Old Dominion ...